Clinical Trial Update: Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing pembrolizumab plus neoadjuvant chemotherapy to neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Esophageal Squamous Cell Carcinoma | Phase 3 | Status: RECRUITING